Zydus Lifesciences secures USFDA tentative approval for Olaparib tablets

Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers in patients who have specific genetic mutations, specifically in the BRCA gene or other homologous recombination repair (HRR) genes. Shares of Zydus Lifesciences Ltd ended at ₹943.80, up by ₹7.55, or 0.81%, on the BSE.

Source link